Monthly Archives | March 2016

The Birth of Biosimilars in the US

We’ve become familiar, and even comfortable, with the concept of generic drugs. These medications are identical, or “bioequivalent,” to a brand-name pharmaceutical.   According to the U.S. Food and Drug Administration, generics must be chemically identical to and match the branded drug in dosage form, safety, strength, route of administration, quality, performance characteristics and intended […]

What we can learn from Choosing Wisely- an initiative of the ABIM Foundation

Who is responsible for driving healthcare reform? Since 2009, hospitals, insurers, drug and device manufacturers, and other major industries have all made efforts or at least positive gestures to get behind healthcare reform. But what about physicians?   A 2010 article in the New England Journal of Medicine suggests that the medical profession has an […]